A caffeine containing weight loss supplement augments hemodynamic responses after exercise.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

The purpose of the current study was to test hemodynamic responses of a weight loss supplement and determine its effects on hemodynamic variables.

Who Took Part

According to the abstract, 31 participants were involved.

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

31 participants underwent a randomized, double-blind, crossover study design and received a placebo or supplement on two separate days.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

Baseline measures of all variables were assessed prior to exercise.

Immediately post-exercise, hemodynamic measures were recorded at multiple time points.

What Was Measured

PubMed files the paper under topics including Blood Pressure, Caffeine, Dietary Supplements, Exercise, Hemodynamics, Pulse Wave Analysis and Vascular Resistance.

Author keywords: Arterial compliance and Post-exercise hypotension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 31 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (International journal of cardiology), a journal based in Netherlands.

More context: the Copper (Supplement) compound page, all human trials.